(Q668093)

atorvastatin (English)

19 October 2016

2 references

inferred from InChIKey

based on heuristic

inferred from InChI

chemical formula

C₃₃H₃₅FN₂O₅

0 references

canonical SMILES

CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4

1 reference

atorvastatin (English)

19 November 2016

isomeric SMILES

CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4

1 reference

atorvastatin (English)

https://www.whocc.no/atc_ddd_index/?code=C10AA05

19 November 2016

defined daily dose

20 milligram

route of administration

oral administration

1 reference

reference URL

1 reference

14 February 2018

World Health Organisation international non-proprietary name

atorvastatin (English)

2 references

atorvastatin (English)

medical condition treated

19 October 2016

published in

Recommended INN: List 35

publication date

1995

1 reference

13 December 2016

coronary artery disease

1 reference

13 December 2016

familial hyperlipidemia

1 reference

13 December 2016

2 references

13 December 2016

2 October 2018

lipedema

1 reference

2 October 2018

heart disease

1 reference

2 October 2018

arterial hypertension

1 reference

2 October 2018

rare dyslipidemia

1 reference

2 October 2018

cerebral infarction

1 reference

significant drug interaction

2 October 2018

(S)-(−)-colchicine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fenofibrate

1 reference

A reference set of clinically relevant adverse drug-drug interactions

gemfibrozil

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ciprofibrate

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(2R)-daptomycin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

bezafibrate

1 reference

A reference set of clinically relevant adverse drug-drug interactions

itraconazole

hepatotoxicity

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fenofibrate

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fosamprenavir

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fosamprenavir

1 reference

A reference set of clinically relevant adverse drug-drug interactions

cyclosporine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

cyclosporine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ciprofibrate

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(S)-(−)-colchicine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ritonavir

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ritonavir

1 reference

A reference set of clinically relevant adverse drug-drug interactions

verapamil

1 reference

A reference set of clinically relevant adverse drug-drug interactions

verapamil

1 reference

A reference set of clinically relevant adverse drug-drug interactions

diltiazem

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ranolazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

atazanavir

1 reference

A reference set of clinically relevant adverse drug-drug interactions

atazanavir

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(2R)-daptomycin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

bezafibrate

1 reference

A reference set of clinically relevant adverse drug-drug interactions

gemfibrozil

1 reference

A reference set of clinically relevant adverse drug-drug interactions

itraconazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

itraconazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

erythromycin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

erythromycin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clarithromycin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clarithromycin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

posaconazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

posaconazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tipranavir

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tipranavir

1 reference

A reference set of clinically relevant adverse drug-drug interactions

lopinavir

1 reference

A reference set of clinically relevant adverse drug-drug interactions

lopinavir

1 reference

A reference set of clinically relevant adverse drug-drug interactions

saquinavir

1 reference

A reference set of clinically relevant adverse drug-drug interactions

saquinavir

1 reference

A reference set of clinically relevant adverse drug-drug interactions

darunavir

1 reference

A reference set of clinically relevant adverse drug-drug interactions

darunavir

1 reference

A reference set of clinically relevant adverse drug-drug interactions

cobicistat

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Ketoconazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Ketoconazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

3-hydroxy-3-methylglutaryl-CoA reductase

subject has role

enzyme inhibitor

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

2949

Australian pregnancy category D

17 August 2016

legal status (medicine)

medical prescription

inception

17 December 1996

applies to jurisdiction

United States of America

1 reference

PMCID

5753395

pregnancy category

1 reference

imported from Wikimedia project

English Wikipedia

US pregnancy category X

1 reference

imported from Wikimedia project

English Wikipedia

LiverTox likelihood score

LiverTox toxicity likelihood category A

1 reference

8 April 2021

https://www.ncbi.nlm.nih.gov/books/n/livertox/Atorvastatin

3 August 2017

2 references

5 March 2018

Medical Subject Headings

MeSH descriptor ID

D000069059

15 March 2018

anticholesteremic agents

1 reference

National Library of Spain ID

Medical Subject Headings

15 March 2018

0 references

0 references

0 references

Atorvastatin

0 references

Identifiers

XX544533

1 reference

reference URL

http://datos.bne.es/tema/XX544533.html

InChI

InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1

1 reference

atorvastatin (English)

XUKUURHRXDUEBC-KAYWLYCHSA-N

19 November 2016

InChIKey

2 references

atorvastatin (English)

19 November 2016

ChEBI release 2020-09-01

CAS Registry Number

134523-00-5

2 references

atorvastatin (English)

XUKUURHRXDUEBC-KAYWLYCHSA-N

19 November 2016

InChIKey

9 April 2021

https://commonchemistry.cas.org/detail?cas_rn=134523-00-5

1 reference

Atorvastatin (English)

19 November 2016

1 reference

atorvastatin (English)

19 November 2016

Reaxys registry number

8373630

1 reference

atorvastatin (English)

19 October 2016

ChEBI ID

39548

mapping relation type

1 reference

ATORVASTATIN (English)

19 November 2016

1 reference

MSBNK-Athens_Univ-AU112901

ATORVASTATIN (English)

19 November 2016

1 reference

MassBank accession ID

SM859301

0 references

SM859351

0 references

0 references

MSBNK-Athens_Univ-AU112902

0 references

MSBNK-Athens_Univ-AU112903

0 references

MSBNK-Athens_Univ-AU112904

0 references

MSBNK-Athens_Univ-AU112905

0 references

MSBNK-Athens_Univ-AU112906

0 references

MSBNK-Athens_Univ-AU112907

0 references

MSBNK-Athens_Univ-AU112908

0 references

MSBNK-Athens_Univ-AU112909

0 references

MSBNK-Athens_Univ-AU112910

0 references

MSBNK-Athens_Univ-AU112911

0 references

MSBNK-Athens_Univ-AU112951

0 references

MSBNK-Athens_Univ-AU112952

0 references

MSBNK-Athens_Univ-AU112953

0 references

MSBNK-Athens_Univ-AU112954

0 references

MSBNK-Athens_Univ-AU112955

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

splash10-052f-0000980000-6751fefdee0a257e52f8

0 references

splash10-0006-0000900000-4009a70e947dcceb6e0f

0 references

splash10-0006-0085900000-e1a4447e4c9a4bda83b2

0 references

splash10-0udi-0092100000-4a5517154ad5f7375ea2

0 references

splash10-0a4i-0000090000-e741fcb91eb29d1032cb

0 references

splash10-0a4i-0000090000-ae5c999b091a2bc93933

0 references

splash10-0a4i-0000190000-dd563e18b1f0f74aadd5

0 references

splash10-0zfs-0007960000-cb66a18d2f0a687261ba

0 references

splash10-002b-0059000000-0942bc1e35434cd7d0d3

0 references

splash10-004i-0093000000-f42ba46820a3cf3295c5

0 references

splash10-00kf-0000900000-fdd41dae94afd3f4d3c5

0 references

splash10-0a4i-0000490000-25199beeece682c7de9e

0 references

splash10-0006-0020900000-71cacdfc979c4386762b

0 references

splash10-0udi-0092000000-38374b1412250df34777

0 references

splash10-0udi-0090000000-87710909ebad67c88f3b

0 references

splash10-0udj-0190000000-60e7ef3dc3f76db11c5f

0 references

splash10-0f72-0290000000-e8c2cda8588874b2aaa5

0 references

splash10-0a4i-0000490000-a5ee6b466e73e9e72383

0 references

splash10-0006-0011900000-b8fc562d4be5ffb07f59

0 references

splash10-0udi-0092000000-df78998b01951a3dd03a

0 references

splash10-0udi-0090000000-19c391db652668c97d59

0 references

splash10-0udj-0190000000-931a1911dcd7ec9dbbc8

0 references

splash10-0f72-0290000000-6157ef91cb98aeef5cf7

0 references

splash10-00kf-0000900000-cd6fb2c00146543cbb47

0 references

splash10-0udj-0005910000-b09ba5f3b86948c7f3cb

0 references

splash10-0a4i-0000090000-6f297ca79ae1761aac33

0 references

splash10-0002-1009300000-9479520f395dcdd585e7

0 references

splash10-004i-0092000000-9b561b8d35c3bdc5e46a

0 references

splash10-004i-0090000000-3aad87273e7f9942a50f

0 references

splash10-01t9-1090000000-3f0efff41ebdb5320ce4

0 references

splash10-03di-2090000000-0227638704b90c4249d0

0 references

splash10-0a4i-0000090000-65c729c6734f6533c431

0 references

splash10-0002-1009300000-9122e4479d8c0c32bb0d

0 references

splash10-004i-0092000000-22d639a8882509e1bcdb

0 references

splash10-004i-0090000000-30a0198165bae85fa258

0 references

splash10-01t9-1090000000-cb3feea45f5280f05c37

0 references

splash10-03di-2090000000-8db2f70b373277f143c0

0 references

splash10-0udj-0005910000-a63c845ca248d958068d

0 references

splash10-0f6x-0092420000-fb2c084ecdd5af8f6f7b

0 references

splash10-0a6s-1085190000-9e43612012842effca5a

0 references

HSDB ID

7039

1 reference

Hazardous Substances Data Bank

28 October 2019

ATORVASTATIN (English)

10 May 2021

1 reference

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

DTXSID60274003

reason for deprecated rank

applies to other chemical entity

1 reference

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

DSSTOX compound identifier

0 references

0 references

806-698-0

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.125.464

27 December 2018

ECHA Substance Infocard ID

1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-ß,d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, [R-(R,R)]- (English)

quotation

CAS no.: 134523-00-5 (English)

100.125.464

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.125.464

27 December 2018

1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-ß,d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, [R-(R,R)]- (English)

quotation

CAS no.: 134523-00-5 (English)

1 reference

World Health Organisation international non-proprietary name numeric ID

Atorvastatin (English)

publication date

17 November 2015

7259

1 reference

reference URL

https://mednet-communities.net/inn/db/ViewINN.aspx?i=7259

Guide to Pharmacology Ligand ID

2949

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

2949

atorvastatin (English)

19 November 2016

Atorvastatin

0 references

0 references

0 references

1 reference

atorvastatin (English)

19 November 2016

1 reference

Atorvastatin (English)

Human Metabolome Database ID

4 October 2016

0 references

1 reference

atorvastatin (English)

MedlinePlus drug identifier

19 November 2016

a600045

0 references

PatientsLikeMe treatment ID

0 references

1 reference

atorvastatin (English)

19 November 2016

0 references

1 reference

1 reference

electronic Essential Medicines List medicine ID

atorvastatin (English)

19 October 2016

0 references

1 reference

6 April 2020

0 references

0 references

1 reference

28 October 2013

Microsoft Academic ID

2777482532

0 references

New York Times topic ID

0 references

1 reference

26 January 2022

https://docs.openalex.org/download-snapshot/snapshot-data-format

1 reference

imported from Wikimedia project

1HWK (English)

19 October 2016

1 reference

1 reference

German Wikipedia

UK Parliament thesaurus ID

521509

subject named as

Atorvastatin

0 references

UMLS CUI

C0286651

1 reference

atorvastatin (English)

inferred by common MeSH mappings on source and on Wikidata

19 November 2016

C0082029

1 reference

based on heuristic

25 May 2023

0 references

0 references

WordNet 3.1 Synset ID

02757426-n

1 reference